Akums Drugs (AKUMS) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2025Income Metrics
Revenue
41.2B
Gross Profit
16.8B
40.91%
Operating Income
3.1B
7.46%
Net Income
3.4B
8.35%
Balance Sheet Metrics
Total Assets
41.1B
Total Liabilities
10.5B
Shareholders Equity
30.6B
Debt to Equity
0.34
Cash Flow Metrics
Operating Cash Flow
2.6B
Free Cash Flow
1.9B
Revenue & Profitability Trend
Akums Drugs Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 41.2B | 41.8B | 34.7B | 36.5B | 27.0B |
| Cost of Goods Sold | 24.3B | 25.5B | 23.1B | 23.8B | 17.2B |
| Gross Profit | 16.8B | 16.3B | 11.7B | 12.7B | 9.8B |
| Operating Expenses | 5.1B | 6.1B | 4.5B | 3.7B | 2.8B |
| Operating Income | 3.1B | 3.6B | 1.9B | 3.2B | 2.3B |
| Pre-tax Income | 3.5B | -452.8M | 1.5B | -1.9B | 1.7B |
| Income Tax | 14.8M | -460.7M | 524.8M | 576.8M | 488.3M |
| Net Income | 3.4B | 7.9M | 978.2M | -2.5B | 1.2B |
| EPS (Diluted) | - | ₹0.05 | ₹6.21 | -₹15.94 | ₹7.80 |
Income Statement Trend
Akums Drugs Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 22.7B | 19.4B | 19.2B | 18.9B | 11.6B |
| Non-Current Assets | 18.4B | 15.8B | 13.4B | 11.8B | 10.1B |
| Total Assets | 41.1B | 35.2B | 32.7B | 30.7B | 21.7B |
| Liabilities | |||||
| Current Liabilities | 8.9B | 12.1B | 12.7B | 12.7B | 5.8B |
| Non-Current Liabilities | 1.6B | 15.9B | 12.8B | 11.7B | 7.0B |
| Total Liabilities | 10.5B | 28.0B | 25.4B | 24.4B | 12.8B |
| Equity | |||||
| Total Shareholders Equity | 30.6B | 7.2B | 7.2B | 6.3B | 8.9B |
Balance Sheet Composition
Akums Drugs Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 3.5B | -452.8M | 1.5B | -1.9B | 1.7B |
| Operating Cash Flow | 2.6B | 564.4M | 1.4B | -7.9B | 1.1B |
| Investing Activities | |||||
| Capital Expenditures | -2.6B | -2.9B | -2.9B | -2.6B | -818.7M |
| Investing Cash Flow | -5.7B | -3.5B | -3.1B | -2.4B | -1.4B |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 1.6B | -491.9M | 1.8B | 2.6B | -735.2M |
| Free Cash Flow | 1.9B | 1.9B | -1.5B | -2.3B | 478.0M |
Cash Flow Trend
Akums Drugs Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
23.69
Forward P/E
19.31
Price to Book
2.69
Price to Sales
1.99
Profitability Ratios
Profit Margin
8.21%
Operating Margin
5.11%
Return on Equity
18.17%
Return on Assets
5.03%
Financial Health
Current Ratio
2.54
Debt to Equity
2.88
Per Share Data
EPS (TTM)
₹22.58
Book Value per Share
₹198.98
Revenue per Share
₹275.21
Financial data is updated regularly. All figures are in the company's reporting currency.